Danaher Corporation $DHR Shares Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC lifted its stake in Danaher Corporation (NYSE:DHR) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,000 shares of the conglomerate’s stock after purchasing an additional 5,000 shares during the quarter. Danaher comprises 3.4% of Sivik Global Healthcare LLC’s portfolio, making the stock its 8th biggest holding. Sivik Global Healthcare LLC’s holdings in Danaher were worth $5,539,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of DHR. BlackRock Inc. purchased a new position in Danaher during the second quarter worth $10,492,520,000. Jupiter Topco LLC bought a new position in Danaher during the second quarter valued at $1,456,317,000. Generation Investment Management LLP purchased a new stake in shares of Danaher in the second quarter valued at $1,287,949,000. Bank of America Corp DE purchased a new stake in shares of Danaher in the second quarter valued at $993,846,000. Finally, Legal & General Group Plc bought a new stake in shares of Danaher in the 2nd quarter worth about $801,056,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 1.4%

Shares of DHR traded up $3.09 during trading hours on Tuesday, reaching $224.29. 2,780,443 shares of the company traded hands, compared to its average volume of 4,442,988. The stock’s fifty day moving average price is $211.85 and its 200 day moving average price is $194.88. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm has a market cap of $157.67 billion, a price-to-earnings ratio of 39.85, a PEG ratio of 2.74 and a beta of 0.76. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the firm posted $0.77 EPS. The firm’s revenue was up 5.5% compared to the same quarter last year. Sell-side analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is currently 28.42%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Morgan Stanley increased their price objective on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday. Evercore reissued an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Finally, TD Cowen upped their target price on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.